<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04092829</url>
  </required_header>
  <id_info>
    <org_study_id>1906-VLC-067-JB</org_study_id>
    <nct_id>NCT04092829</nct_id>
  </id_info>
  <brief_title>Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer</brief_title>
  <acronym>PREECLAM-2019</acronym>
  <official_title>Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Valenciano de Infertilidad, IVI VALENCIA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IVI Bilbao</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IVI Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IVI Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IVI Sevilla</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IVI Vigo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IVI Roma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Valenciano de Infertilidad, IVI VALENCIA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identifying modifiable factors that contribute to preeclampsia risk associated with assisted
      reproduction can improve maternal health. Recent studies have shown an increased risk for
      hypertensive disorders of pregnancy after in vitro fertilization, particularly for
      pregnancies occurring during a hormone replacement therapy such a donor egg recipient and a
      frozen embryo transfer. This risk may be partly attributable to the degree by which the
      assisted reproductive treatment affects the maternal hormonal environment, when the corpus
      luteum is a major source of reproductive hormones. On the other hand, cryopreserved embryos
      are usually thawed and replaced in in a natural or hormonally manipulated cycle; on this
      point, frozen embryo transfer is associated with better perinatal outcome regarding preterm
      birth and low birth weight yet higher risk of large for gestational age and macrosomia
      compared to fresh transfer. The objective of our study is to investigate whether the absence
      of corpus luteum adversely affects pregnancy and to analyse if there are differences in the
      perinatal outcomes due to differences in the endometrial preparation protocol for a frozen
      embryo transfer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized prospective analysis.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of pre-eclampsia during pregnancy.</measure>
    <time_frame>12 months</time_frame>
    <description>Presence or absence of pre-eclampsia during pregnancy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding during pregnancy</measure>
    <time_frame>12 months</time_frame>
    <description>Presence or absence of Bleeding during pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertension during pregnancy</measure>
    <time_frame>12 months</time_frame>
    <description>Presence or absence of Hypertension during pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eclampsia during pregnancy</measure>
    <time_frame>12 months</time_frame>
    <description>Presence or absence of Eclampsia during pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preeclampsia during pregnancy</measure>
    <time_frame>12 months</time_frame>
    <description>Presence or absence of Preeclampsia during pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retarded intrauterine growth during pregnancy</measure>
    <time_frame>12 months</time_frame>
    <description>Presence or absence of retarded intrauterine growth at birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Premature detachment of normoinserted placenta during pregnancy</measure>
    <time_frame>12 months</time_frame>
    <description>Presence or absence of premature detachment of normoinserted placenta during pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type II Diabetes during pregnancy</measure>
    <time_frame>12 months</time_frame>
    <description>Presence or absence of Type II Diabetes during pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Help Sindrome during pregnancy</measure>
    <time_frame>12 months</time_frame>
    <description>Presence or absence of Help Sindrome during pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations in the volume of the amniotic fluid during pregnancy</measure>
    <time_frame>12 months</time_frame>
    <description>Presence or absence of alterations in the volume of the amniotic fluid during pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm premature rupture of membranes during pregnancy.</measure>
    <time_frame>12 months</time_frame>
    <description>Presence or absence of preterm premature rupture of membranes during pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal death</measure>
    <time_frame>12 months</time_frame>
    <description>Presence or absence of fetal death at birth.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Pre-Eclampsia</condition>
  <condition>Frozen Embryo Transfer</condition>
  <arm_group>
    <arm_group_label>FROZEN EMBRYO TRANSFER IN NATURAL CYCLE</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>After confirming ovarian rest (follicles &lt; 10 mm) with menstruation by means of vaginal ultrasound, an ultrasound control of the natural cycle will be carried out, inducing ovulation when an ovulatory follicle of size ≥ 17mm and an endometrium ≥ 7mm are found. Serum estradiol and progesterone values will be determined that day. This induction will be carried out with an ampoule of 250 μg of rHCG (Ovitrelle®). After the injection of Ovitrelle®, the administration of micronized vaginal progesterone (Progeffik® or Utrogestan®) 200 mg/ 12 hours and 7 days after the injection, thawing and transfer of a frozen euploid blastocyst will begin 48 hours later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After confirming ovarian rest (follicles &lt; 10 mm) with menstruation by vaginal ultrasound, hormone replacement therapy with oestrogens (6 mg/day of oral oestradiol valerate - Progynova® or Progyluton®- or 150 ug/48 h of oestradiol in patches - Evopad®) will be started on day 2-3 of the cycle. On day 10-15 of treatment an ultrasound scan will be performed to assess endometrial growth and ovarian rest. After confirming an endometrial thickness ≥ 7mm by vaginal ultrasound, ovaries with follicles smaller than 10 mm, blood estradiol &gt;100 pg/ml and serum progesterone &lt; 1 ng/ml, luteal phase support will begin with the administration of 400 mg of micronized vaginal progesterone every 12 hours, a total of 10 shots, prior to embryo transfer of a thawed euploid blastocyst. same day. If the level of serum progesterone on the day of transfer is less than 9.2 ng/ml, a daily injection of subcutaneous progesterone (Prolutex®) will be added on the same day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE</intervention_name>
    <description>The intervention group will be prepared with hormone replacement therapy with estrogens according to usual clinical practice. Frozen embryos will be transferred after ten doses of exogenous progesterone.</description>
    <arm_group_label>FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  All patients who, after IVF-PGT-A treatment with their own oocytes, present a euploid
             embryo for transfer.

          -  Transfer of a single euploid embryo

        Exclusion criteria:

          -  Moderate or high smoking (&gt; 5 cigarettes/day)

          -  BMI ≥30 kg/m2

          -  Chronic hypertension

          -  History of preeclampsia in previous pregnancies

          -  History of delayed uterine growth and placental insufficiency in previous pregnancies

          -  Use of donor sperm

          -  Woman's age ≥44 years

          -  Women with menstrual cycles longer than 35 days
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JOSE BELLVER PRADAS, MDPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IVIRMA VALENCIA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JOSE BELLVER PRADAS, MDPhD</last_name>
    <phone>+34963050900</phone>
    <email>jose.bellver@ivirma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ivi Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LAURA CARACENA, NURSE</last_name>
      <phone>+34 687 03 19 78</phone>
      <email>LAURA.CARACENA@IVIRMA.COM</email>
    </contact>
    <contact_backup>
      <last_name>ANA SAEZ, COORDINATOR</last_name>
      <phone>963050900</phone>
      <phone_ext>11058</phone_ext>
      <email>ANA.SAEZ@IVIRMA.COM</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pre-Eclampsia</keyword>
  <keyword>Corpus Luteum</keyword>
  <keyword>Frozen embryo transfer</keyword>
  <keyword>Endometrial preparation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

